Study procedures and endpoints
disability, CRS
The primary endpoint of this study was safety. CRS and ICANS was defined and graded according to published criteria.Secondary endpoints were defined as CT103A levels in blood and circulating serum AQP4 antibodies levels detected by CBA. Key exploratory outcomes included efficacy, disability and life quality, measurement of select cytokines, serum BCMA, and anti-drug antibody testing.